FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaccine Reaction COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Neoplasms Nidovirales Infections Oncology Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kocaeli University School of Medicine Dep. of Nuclear Medicine

Kocaeli, tr-41650, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients referred for post-vaccination FDG PET/CT imaging

Exclusion criteria

Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria

Treatment and study plan

F-18 FDG PET/CT imaging

Diagnostic Test

Oncological imaging

Pfizer/biontech mRNA vaccine

Biological

COVID-19 vaccine

Primary outcomes

to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine

Time frame: 5 month

Frequency of metabolic changes
to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine

Time frame: 5 month

FDG intensity of metabolic changes

Sponsors and collaborators

Lead sponsor

Kocaeli University

Other

Registry information

Official study title

Evaluation of Metabolic Changes in FDG PET/CT Imaging After mRNA-based COVID-19 Vaccination

Acronym: fdg

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Mar 8, 2022
Registry last updated: Mar 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed